ArticleBlood advances2019

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.

Haris Ali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.